What are cholesterol absorption inhibitor drugs?

cholesterol absorption inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting NPC1L1). 0 are currently marketed, with 5 more in clinical development.

cholesterol absorption inhibitor

0 marketed 5 in Phase 3

This page covers all cholesterol absorption inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting NPC1L1, NPC1L1 (Niemann-Pick C1-Like 1).

Targets

NPC1L1 · NPC1L1 (Niemann-Pick C1-Like 1)

Phase 3 pipeline (5)

MK-0653, ezetimibe · Organon and Co · Cardiovascular
Ezetimibe inhibits the absorption of cholesterol in the small intestine.
Monotherapy ezetimibe · NewAmsterdam Pharma · Cardiovascular
Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter.
MK0653, ezetimibe · Organon and Co · Cardiovascular
Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter.
Placebo to Ezetimibe · Amgen · Cardiovascular
Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter.
laropiprant/niacin (MK0524A) · Merck Sharp & Dohme LLC · Cardiovascular
Laropiprant/niacin is a combination of a cholesterol absorption inhibitor and a niacin receptor agonist that works to increase HDL cholesterol and reduce triglycerides.